[go: up one dir, main page]

WO2025017168A1 - Nouveaux micro-gènes d'utrophine optimisés - Google Patents

Nouveaux micro-gènes d'utrophine optimisés Download PDF

Info

Publication number
WO2025017168A1
WO2025017168A1 PCT/EP2024/070500 EP2024070500W WO2025017168A1 WO 2025017168 A1 WO2025017168 A1 WO 2025017168A1 EP 2024070500 W EP2024070500 W EP 2024070500W WO 2025017168 A1 WO2025017168 A1 WO 2025017168A1
Authority
WO
WIPO (PCT)
Prior art keywords
utrophin
micro
seq
gene
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/070500
Other languages
English (en)
Inventor
Simon GUIRAUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Genethon
Universite D'Evry Val D'Essonne
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Genethon
Universite D'Evry Val D'Essonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Genethon, Universite D'Evry Val D'Essonne filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO2025017168A1 publication Critical patent/WO2025017168A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy

Definitions

  • the present invention relates to novel optimized utrophin micro-genes which are useful in the treatment or prevention of dystrophic diseases, especially Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).
  • DMD Duchenne muscular dystrophy
  • BMD Becker muscular dystrophy
  • DMD Duchenne muscular dystrophy
  • DG dystrophin-glycoprotein
  • BMD Becker muscular dystrophy
  • dystrophin gene restoration-based therapeutic strategies are mutation dependent and consequently limited to a specific subset of patients (respectively 13 and 11% of the patients).
  • rAAV-mediated systemic gene therapy to deliver a truncated but partially functional micro-dystrophin (pDYS) gene is currently under investigation in clinical trials bringing hope for an effective therapy to the DMD community.
  • pDYS micro-dystrophin
  • Utrophin was described as functional and structural autosomal paralogue of dystrophin able to compensate for the lack of dystrophin in DMD and to prevent the dystrophic pathology. Unlike dystrophin, utrophin is naturally expressed in dystrophic muscles and no immune response was observed with utrophin gene therapy. Besides, as demonstrated by the work of the Chamberlain team, the administration of a murine codon-optimized micro-utrophin (AR4-R21/ACT) transgene to adult dystrophin' 7utrophin" (mdx:utrn ⁇ ) double-knockout mice may be a treatment option for DMD.
  • AR4-R21/ACT murine codon-optimized micro-utrophin
  • mdx:utrn ⁇ adult dystrophin' 7utrophin
  • the present invention aims at alleviating or curing the devastating Duchenne muscular dystrophy (DMD) as well as Becker muscular dystrophy (BMD) by providing a robust alternative to pDYS approaches currently under investigation in clinic.
  • DMD Duchenne muscular dystrophy
  • BMD Becker muscular dystrophy
  • the present invention offers a promising optimized utrophin-based gene therapy (pUTR) applicable to all Duchenne and Becker patients by increasing the dystrophin- related protein, utrophin. More specifically, the present invention is based on the use of recombinant adeno-associated virus (rAAV) to deliver and to express novel optimized micro- utrophin genes for gene replacement strategy.
  • pUTR utrophin-based gene therapy
  • rAAV recombinant adeno-associated virus
  • the expression “optimized micro-utrophin genes” or “optimized utrophin micro-genes” means that said genes encode micro-utrophins which have a better therapeutic activity than the previously described AR4-R21/ACT micro-utrophin (see e.g. Odom et al., 2008, Mol Then, 16(9): 1539-45).
  • the present invention therefore has various advantages, including the fact that the administration of pUTR as a transgene therapy product according to the invention does not induce any immune response against the exogenous transgene since this protein is naturally expressed in dystrophic muscle cells. Besides and based on the pUTR transgenes of the present invention, the efficiency of the pUTR can be ameliorated, e.g. by enhancing its binding to the actin cytoskeleton.
  • an element means one element or more than one element.
  • ranges throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
  • nucleic acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated.”
  • An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a nonnative environment such as, for example, a host cell.
  • A refers to adenosine
  • C refers to cytosine
  • G refers to guanosine
  • T refers to thymidine
  • U refers to uridine.
  • nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence.
  • the phrase nucleotide sequence that encodes a protein or a RNA or a cDNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).
  • Encoding refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
  • a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
  • Both the coding strand the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
  • nucleotide as used herein is defined as a chain of nucleotides.
  • nucleic acids are polymers of nucleotides.
  • nucleic acids and polynucleotides as used herein are interchangeable.
  • nucleic acids are polynucleotides, which can be hydrolyzed into the monomeric “nucleotides.” The monomeric nucleotides can be hydrolyzed into nucleosides.
  • polynucleotides include, but are not limited to, all nucleic acid sequences which are obtained by any means available in the art, including, without limitation, recombinant means, i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCR and the like, and by synthetic means.
  • recombinant means i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCR and the like, and by synthetic means.
  • peptide polypeptide
  • protein are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds.
  • a protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein’s or peptide’s sequence.
  • Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
  • a protein may be “altered” and contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity is retained.
  • negatively charged amino acids may include aspartic acid and glutamic acid; positively amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, serine and threonine, and phenylalanine and tyrosine.
  • a “variant”, as used herein, refers to an amino acid sequence that is altered by one or more amino acids.
  • the variant may have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties, e. g. replacement of leucine with isoleucine.
  • a variant may also have “non-conservative” changes, e.g., replacement of a glycine with a tryptophan.
  • Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art.
  • active fragment refers to a portion or portions of a full length sequence that retain the biological function of the full length sequence encoding a protein, such as utrophin.
  • Identity or “homologous” refers to the sequence identity or sequence similarity between two polypeptides or between two nucleic acid molecules. When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous or identical at that position.
  • the percent of homology/identity between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared X 100. For example, if 6 of 10 of the positions in two sequences are matched then the two sequences are 60% identical. Generally, a comparison is made when two sequences are aligned to give maximum homology/identity.
  • a “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell.
  • vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses.
  • the term “vector” includes an autonomously replicating plasmid or a virus.
  • the term should also be construed to include nonplasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the like.
  • viral vectors examples include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, and the like.
  • “Viral vector” refers to a non-replicating, non-pathogenic virus engineered for the delivery of genetic material into cells.
  • viral vectors viral genes essential for replication and virulence are replaced with an expression cassette for the gene of interest.
  • the viral vector genome comprises the expression cassette flanked by the viral sequences required for viral vector production.
  • “Expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed.
  • An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system.
  • Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.
  • promoter as used herein is defined as a nucleic acid sequence recognized by the transcriptional machinery of the cell, or introduced transcriptional machinery, required to initiate the specific transcription of a polynucleotide sequence, in particular of a gene of interest.
  • promoter/regulatory sequence means a nucleic acid sequence, which is required for expression of a gene product (i.e. the gene of interest) operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements, which are required for expression of the gene product.
  • the promoter/regulatory sequence may, for example, be one, which expresses the gene product in a tissue specific manner.
  • operably linked refers to the juxtaposition of the gene of interest with the sequences controlling its transcription. There may be additional residues between the promoter and the gene of interest so long as this functional relationship is preserved.
  • a “constitutive” promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.
  • an “inducible” promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell substantially only when an inducer which corresponds to the promoter is present in the cell or when a repressor thereof is removed.
  • tissue-specific promoter is a nucleotide sequence which, when operably linked with a polynucleotide encodes or specified by a gene, causes the gene product to be produced in a cell preferentially if the cell is a cell of the tissue type corresponding to the promoter.
  • a “gene of interest” or “transgene” is a gene useful for a particular application, such as with no limitation, diagnosis, reporting, modifying, therapy and genome editing.
  • the gene of interest may be a therapeutic gene, a reporter gene or a genome-editing enzyme.
  • the gene of interest is a human gene.
  • the gene of interest is a functional version of a gene or a fragment thereof.
  • the functional version of said gene includes the wild-type gene, a variant gene such as variants belonging to the same family and others, or a truncated version, which preserves the functionality of the encoded protein at least partially.
  • a functional version of a gene is useful for replacement or additive gene therapy to replace a gene, which is deficient or non-functional in a patient.
  • the gene of interest is a gene which inactivates a dominant allele causing an autosomal dominant genetic disease.
  • a fragment of a gene is useful as recombination template for use in combination with a genome editing enzyme.
  • the gene of interest may encode a protein of interest for a particular application (for example an antibody or antibody fragment, a genome-editing enzyme) or a RNA.
  • the protein is a therapeutic protein including a therapeutic antibody or antibody fragment, or a genome-editing enzyme.
  • the RNA is a therapeutic RNA.
  • the gene of interest is a functional gene able to produce the encoded protein, peptide or RNA in the target cells of the disease, in particular muscle cells.
  • the RNA is advantageously complementary to a target DNA or RNA sequence or binds to a target protein.
  • the RNA is an interfering RNA such as a shRNA, a microRNA, a guide RNA (gRNA) for use in combination with a Cas enzyme or similar enzyme for genome editing, an antisense RNA capable of exon skipping such as a modified small nuclear RNA (snRNA) or a long non-coding RNA.
  • the interfering RNA or microRNA may be used to regulate the expression of a target gene involved in muscle disease.
  • the guide RNA in complex with a Cas enzyme or similar enzyme for genome editing may be used to modify the sequence of a target gene, in particular to correct the sequence of a mutated/deficient gene or to modify the expression of a target gene involved in a disease, in particular a neuromuscular disease.
  • the antisense RNA capable of exon skipping is used in particular to correct a reading frame and restore expression of a deficient gene having a disrupted reading frame.
  • the RNA is a therapeutic RNA.
  • said gene of interest encodes a therapeutic protein or therapeutic ribonucleic acid that can be any protein or ribonucleic acid providing a therapeutic effect to skeletal muscular cells.
  • the said therapeutic protein can be any protein providing a therapeutic effect outside of the skeletal muscular cells. The said therapeutic protein can indeed be secreted by the said cells.
  • abnormal when used in the context of organisms, tissues, cells or components thereof, refers to those organisms, tissues, cells or components thereof that differ in at least one observable or detectable characteristic (e.g., age, treatment, time of day, etc.) from those organisms, tissues, cells or components thereof that display the “normal” (expected) respective characteristic. Characteristics, which are normal or expected for one cell or tissue type, might be abnormal for a different cell or tissue type.
  • a subject can be a mammal, e.g. a human, a dog, but also a mouse, a rat or a nonhuman primate.
  • the patient, subject or individual is a human.
  • a “disease” or a “pathology” is a state of health of a subject wherein the subject cannot maintain homeostasis, and wherein if the disease is not ameliorated then the subject’s health continues to deteriorate.
  • a “disorder” in a subject is a state of health in which the subject is able to maintain homeostasis, but in which the subject’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the subject’s state of health.
  • a disease or disorder is “alleviated” or “ameliorated” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is reduced. This also includes halting progression of the disease or disorder.
  • a disease or disorder is “cured” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is eliminated.
  • a “therapeutic” treatment is a treatment administered to a subject who exhibits signs of pathology, for the purpose of diminishing or eliminating those signs.
  • a “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs of pathology or has not be diagnosed for the pathology yet, for the purpose of preventing or postponing the occurrence of those signs.
  • treating a disease or disorder means reducing the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject.
  • Disease and disorder are used interchangeably herein in the context of treatment.
  • an “effective amount” of a compound is that amount of compound which is sufficient to provide a beneficial effect to the subject to which the compound is administered.
  • the phrase “therapeutically effective amount”, as used herein, refers to an amount that is sufficient or effective to prevent or treat (delay or prevent the onset of, prevent the progression of, inhibit, decrease or reverse) a disease or condition, including alleviating symptoms of such diseases.
  • An “effective amount” of a delivery vehicle is that amount sufficient to effectively bind or deliver a compound.
  • the present invention concerns a micro-utrophin (pUTR), advantageously a functional micro-utrophin, more advantageously of human origin.
  • pUTR micro-utrophin
  • micro-utrophin means a peptide or protein which is shorter than the native or wild type utrophin.
  • micro-utrophin and “mini-utrophin” have the same meaning.
  • micro-utrophi- dystrophin will be used.
  • a micro-utrophin according to the invention has a size of more than 30% or 35%, or even more than 40% of the size of the full-length utrophin (e.g. 3433 amino acids for the human version).
  • the micro-utrophin advantageously contains more than 1165 amino acids, still advantageously more than 1370 amino acids, e.g. 1380 aa (pUTRl), 1371 aa (pUTR2), or 1393 aa (pUTR3).
  • an active fragment is a portion or portions of the full-length sequence that retain at least some of the biological functions of the full length sequence.
  • a “functional” truncated utrophin or micro-utrophin means that the corresponding peptide or protein is able to perform at least some of the functions of the wild-type utrophin protein and is able to alleviate, at least partially, one or more of the symptoms associated with the absence of a native dystrophin, especially fiber degeneration, inflammation, necrosis, replacement of muscle with scar and fat tissue, muscle weakness, respiratory and cardiac failure, as well as premature death.
  • the micro-utrophin according to the invention displays (to a greater or lesser extent) at least one of the properties disclosed in relation to the micro-utrophin and/or micro-dystrophins of the prior art, especially those disclosed by Yue, etal. (Mol Ther, 2006. 14(1): 79-87) or Kodippili et al. (Human Gene Therapy, 2018, 29 (3), 299-311).
  • DAP DAP-binding with at least one DAP (“dystrophin associated proteins”), especially with syntrophin, dystrobrevin, nNOS and/or PAR-lb proteins; Recruitment of the DAP complex at the sarcolemma;
  • said properties can be tested in vitro on various cells expressing dystrophin, e.g. on iPS derived human DMD myogenic cells, ex vivo on muscle fibres isolated from various animal models, or in vivo based on animal models or even on patients suffering from DMD or BMD.
  • Animal models are e.g. the mdx mouse (Foster H. et al., Mol Ther, 2008. 16(11): p. 1825-32), the mdx 4cN mouse (Decrouy et al., Gen Ther, 1997. 4(5): 401- 8), the D2.B10-mdx/J mouse (Coley et al., Human Molecular genetics, 2016.
  • the mouse model is commonly used to test new constructs encoding microdystrophins. However, this model has drawbacks because the mouse displays a less severe form of the disease, without immune reactions.
  • the other animal model is the dog which is considered more reliable to predict the therapeutic potential of a gene therapy product in humans.
  • the rat model as disclosed by Larcher et al. (Pios One, 2014, 9(10), el 10371) is also very interesting since it displays cardiomyopathy.
  • Fig. 1 A the full length dystrophin (Fig. 1 A) is characterized by different domains: a N-terminal domain (NTD);
  • R1 to R24 spectrin-like repeats or rod domains
  • CCD cysteine-rich domain
  • CCD C-terminal domain
  • Fig. 1C the full length utrophin (Fig. 1C) is characterized by different domains: a N-terminal domain (NTD);
  • spectrin-like repeats or rod domains R1 to R22
  • CCD cysteine-rich domain
  • C-terminal domain CCD
  • the human utrophin has the following structure:
  • the CRD domain corresponding to amino acids 2812 to 3165 of SEQ ID NO: 1, including the WW domain (corresponding to amino acids 2812 to 2845 of SEQ ID NO: 1) and the ZZ domain (corresponding to amino acids 3065 to 3121 of SEQ ID NO: 1);
  • a micro-utrophin according to the invention has at least one domain lacking, advantageously at least one spectrin-like-repeat (R), compared to the full length utrophin.
  • a micro-utrophin according to the prior art has a structure defined as follows, from its N terminal end and in the following order: a N-terminal domain (NTD); the Hl hinge domain;
  • CCD cysteine-rich domain
  • NTDH1R1R2R3H2R22H4CRD has the structure NTDH1R1R2R3H2R22H4CRD.
  • sequence of such a micro-utrophin is shown in SEQ ID NO: 3.
  • micro-utrophins of the invention contain at least the spectrin-like-repeats of the micro- utrophin of the prior art, i.e. R1-R2-R3 and R22.
  • micro-utrophins according to the invention contain further rod (R) domains compared to the micro-utrophin of the prior art, advantageously at least one or even two chosen in the group consisting of R4, R5, R6, R7, R8, R9 and RIO of utrophin, advantageously of human utrophin, and/or the R16 and R17 of dystrophin, advantageously of human dystrophin.
  • R rod
  • micro-utrophins do not contain R11-R21 of utrophin, advantageously of human utrophin.
  • micro-utrophins of the invention contain at least one key protein binding site, especially for F-actin and possibly for the nNOS protein.
  • micro-utrophins of interest contain the binding site of actin which was shown to lie in repeats 1 to 10 (R1-R10) of the rod domain of utrophin.
  • micro-utrophins of interest contain at least the Rl-3 rod domains of utrophin and at least two further rod domains among R4-10, advantageously two contiguous rod domains, e.g. the R4-5 or R9-10 rod domains of utrophin.
  • the said at least 2 rod domains advantageously the 2 rod domains are selected from the group consisting of R4, R5, R9 and RIO. According to one embodiment, the said at least 2 rod domains, advantageously the 2 rod domains are R4 and R5 or R9 and RIO.
  • micro-utrophins of interest contain the binding site of nNOS which was shown to lie in repeats 16 and 17 (R16, R17) of the rod domain of dystrophin (Lai et al., J. Clin. Invest., 2009. 119:624-635). According to a preferred embodiment, micro- utrophins of interest contain the R16-17 rod domains of dystrophin.
  • the micro-utrophin has the structure CH1CH2H1R1R2R3H2R22H4CR of the utrophin and R16R17 of the dystrophin.
  • a micro-utrophin according to the prior art further comprises at least two other rod domains, advantageously two other rod domains, selected from the group consisting of:
  • such a micro-utrophin further contains the R4 and R5 rod domains, advantageously from utrophin, more advantageously from human utrophin.
  • such a micro-utrophin has the structure NTDH1R1R2R3H2R4R5R22H4CRD.
  • the sequence of such a micro-utrophin is shown in SEQ ID NO: 5.
  • such a micro-utrophin further contains the R9 and RIO rod domains, advantageously from utrophin, more advantageously from human utrophin.
  • such a micro-utrophin has the structure NTDH1R1R2R3H2R9R10R22H4CRD.
  • such a micro-utrophin further contains the R16 and R17 rod domains, advantageously from dystrophin, more advantageously from human dystrophin.
  • such a micro-utrophin has the structure NTDH1R1R2R3H2R16R17R22H4CRD.
  • the micro-utrophin can be considered as a hybrid/chimeric micro- dystrophin/utrophin.
  • the sequence of such a micro-utrophin is shown in SEQ ID NO: 9.
  • micro-utrophins according to the invention lack the following rod domains:
  • such a micro-utrophin contains R1 to R5 and R22;
  • micro-utrophin contains R1 to R3, R9 to RIO and R22;
  • such a micro-utrophin contains R1 to R3 and R22 of utrophin and R16 to R17 of dystrophin.
  • micro-utrophins according to the invention contain: a complete N-terminal domain (NTD), e.g. corresponding to amino acids 1 to 255 of SEQ ID NO: 1 or of SEQ ID NO: 3 a complete cysteine-rich (CRD) domain, e.g. corresponding to amino acids 2812 to 3165 of SEQ ID NO: 1 a partial or full-length C-terminal domain, e.g. the full-length C-terminal domain corresponding to amino acids 3166 to 3433 of SEQ ID NO: 1 at least one hinge (H) domain, chosen in the group consisting of Hl, H2, H3 and H4, advantageously at least Hl and H2, more advantageously Hl, H2 and H4.
  • NTD N-terminal domain
  • CCD cysteine-rich domain
  • H hinge
  • the micro-utrophin protein is deprived of the Rl l, R12, R13, R14, R15, R18, R19, R20, and R21 rod domains of the utrophin gene and of the C-terminal domain (CTD) of the utrophin gene.
  • a micro-utrophin is “substantially identical”, that is, is about 60% identical, preferably about 70% identical, more preferably about 80% identical, even more preferably about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even more preferably about 99% identical to the micro-utrophins disclosed therein, especially those of sequence SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9, advantageously of SEQ ID NO: 7.
  • the present invention relates to an isolated synthetic nucleic acid molecule or a nucleic acid sequence encoding a micro-utrophin protein as disclosed above.
  • said nucleic acid sequence is an ORF (“Open Reading Frame”.
  • said sequence corresponds to a cDNA.
  • e.g. single- or doublestranded DNA or RNA can be used.
  • the nucleic acid sequence encoding a micro-utrophin according to the invention comprises or consists of sequence SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10, advantageously SEQ ID NO: 8.
  • the nucleic acid sequence encoding a micro-utrophin according to the invention is “substantially identical”, that is, is about 60% identical, preferably about 70% identical, more preferably about 80% identical, even more preferably about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or even more preferably about 99% identical to the sequence SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10, advantageously of SEQ ID NO: 8.
  • the nucleic acid sequence encoding the functional micro-utrophin is advantageously of human origin but can also be a canine, a rat or a murine sequence.
  • the nucleic acid sequence originates from the organism it will be administered to (e.g., a human sequence in humans).
  • the nucleic acid sequence encoding the micro-utrophin according to the invention is optimized for use in a given subject, advantageously in humans.
  • this optimized sequence can be modified as follows:
  • the sequence is modified to include a consensus Kozak sequence before AUG start codon within mRNA, to improve initiation of translation.
  • the sequence is optimized based on transfer RNA frequencies in human and GC content is increased to promote RNA stability.
  • codon optimization for humans advantageously leads to 63% of codons being modified and the GC content increased to over 60%. This of course depends on the original (before optimization) micro- utrophin sequence and the target host.
  • the present invention concerns an expression construct (or “expression cassette” or “insert” or “expression system”) comprising the nucleic acid sequence encoding the functional micro-utrophin of the invention.
  • the expression construct comprises the nucleic acid sequence encoding the transgene of interest, in the present case a micro-utrophin (pUTR), the 2 ITR sequences of an AAV vector, but also all the sequences required for a proper expression of said MD, i.e. regulatory elements.
  • pUTR micro-utrophin
  • AAV2 contains 2 ITR sequences of 145 bp each and has a genome of 4682 pb (including the ITR sequences).
  • the expression construct to be introduced in the AAV vector has a length of less than 5 kb, such as less than 4.9, 4.8, 4.7, 4.6 or 4.5 kb.
  • the nucleic acid sequences encoding the micro-utrophin correspond to exons.
  • they are preferably cDNA fragments.
  • the nucleic acid sequence is placed under the control of regulatory sequence(s).
  • the expression of said nucleic acid is governed by a promoter, usually located upstream said sequence.
  • Such promoters can be natural or synthetic (artificial) promoters, inducible or constitutive.
  • the promoter is a ubiquitous promoter or has a low tissue-specificity.
  • the expression vector can harbor the phosphoglycerate kinase 1 (PGK), EFl, ACTA1, P-actin, Desmin, all MCK variants, cardiac Troponin and CMV promoter.
  • PGK phosphoglycerate kinase 1
  • EFl EFl
  • ACTA1 phosphoglycerate kinase 1
  • P-actin ACTA1
  • Desmin all MCK variants
  • cardiac Troponin and CMV promoter phosphoglycerate kinase 1
  • the promoter sequence is chosen in order to adequately govern the expression of the nucleic acid sequence placed under its control, in terms of expression level, but also of tissue specificity.
  • the promoter is a muscle specific promoter.
  • a muscle specific promoter allows a robust expression in the skeletal muscles, in the diaphragm and possibly in the cardiac muscle.
  • Suitable promoters known by the skilled person are e.g. the desmin promoter, the muscle creatine kinase (MCK) promoter, truncated creatine kinase promoters such as e.g. the CK6, CK7 or CK8 promoter, or derivatives thereof such as e.g. the MHCK7 promoter, the Syn promoter, the CMV promoter, MyoD, Myf5, Vcam, Pax3 and Pax7 satellite cell promoter.
  • Another promoter is the synthetic promoter C5-12 (spC5-12).
  • H3 promoter advantageously of sequence SEQ ID NO: 11.
  • transcript stabilization e.g. intron
  • - miRNA target sequences which can inhibit the expression of the sequence encoding the micro-utrophin in non target tissues, in which said expression is not desired, for example where it can be toxic.
  • the intron is selected from the group consisting of a human beta globin b2 (or HBB2) intron, a FIX intron and a chicken beta-globin intron, wherein said intron is optionally a modified intron such as a modified HBB2 intron, a modified FIX intron, or a modified chicken beta-globin intron.
  • HBB2 human beta globin b2
  • FIX FIX intron
  • chicken beta-globin intron wherein said intron is optionally a modified intron such as a modified HBB2 intron, a modified FIX intron, or a modified chicken beta-globin intron.
  • the polyadenylation signal is selected among the human beta globin polyadenylation signal, the bovine growth hormone polyadenylation signal, the SV40 polyadenylation (pA) signal, or another naturally occurring or artificial polyadenylation signal.
  • polyadenylation signal is the SV40 poly A, advantageously of sequence SEQ ID NO: 12.
  • the nucleic acid sequence encoding the microdystrophin is inserted between the ITR ( « Inverted Terminal Repeat ») sequences of an AAV vector, advantageously the ITR of an AAV of serotype 2 (ITR2).
  • the present invention relates to a plasmid or a vector comprising the nucleic acid sequence or the expression construct as disclosed above.
  • the expression system of the invention includes a vector having a suitable tropism, in this case higher for the target tissue(s), advantageously the skeletal muscles and the heart, than for the tissues where the expression of the protein is not desired.
  • such a vector is a viral vector.
  • Viral vectors commonly used in gene therapy in mammals, including humans, are known to those skilled in the art.
  • Such viral vectors are preferably chosen from the following list: vector derived from the herpes virus, baculovirus vector, lentiviral vector, retroviral vector, adenoviral vector and adeno-associated viral vector (AAV).
  • the viral vector is an adeno-associated viral (AAV) vector.
  • AAV adeno-associated viral
  • Adeno-associated viral (AAV) vectors have become powerful gene delivery tools for the treatment of various disorders.
  • AAV vectors possess a number of features that render them ideally suited for gene therapy, including a lack of pathogenicity, moderate immunogenicity, and the ability to transduce post-mitotic cells and tissues in a stable and efficient manner.
  • Expression of a particular gene contained within an AAV vector can be specifically targeted to one or more types of cells by choosing the appropriate combination of AAV serotype, promoter, and delivery method.
  • the encoding sequence is contained within an AAV vector. More than 100 naturally occurring serotypes of AAV are known. Many natural variants in the AAV capsid exist, allowing identification and use of an AAV with properties specifically suited for dystrophic pathologies.
  • AAV viruses may be engineered using conventional molecular biology techniques, making it possible to optimize these particles for cell specific delivery of nucleic acid sequences, for minimizing immunogenicity, for tuning stability and particle lifetime, for efficient degradation, for accurate delivery to the nucleus.
  • the use of AAVs is a common mode of exogenous delivery of DNA as it is relatively non-toxic, provides efficient gene transfer, and can be easily optimized for specific purposes.
  • human serotype 2 is the first AAV that was developed as a gene transfer vector.
  • Other currently used AAV serotypes include AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 and AAV12.
  • non-natural engineered variants and chimeric AAV can also be useful.
  • Desirable AAV fragments for assembly into vectors include the cap proteins, including the vpl, vp2, vp3 and hypervariable regions, the rep proteins, including rep 78, rep 68, rep 52, and rep 40, and the sequences encoding these proteins. These fragments may be readily utilized in a variety of vector systems and host cells.
  • artificial AAV serotypes include, without limitation, AAV with a non-naturally occurring capsid protein.
  • AAV sequence e.g., a fragment of a vpl capsid protein
  • heterologous sequences which may be obtained from a different selected AAV serotype, noncontiguous portions of the same AAV serotype, from a non-AAV viral source, or from a non- viral source (i.e.
  • capsid comprises VP capsid proteins derived from at least two different AAV serotypes, or comprises at least one chimeric VP protein combining VP protein regions or domains derived from at least two AAV serotypes).
  • An artificial AAV serotype may be, without limitation, a chimeric AAV capsid, a recombinant AAV capsid, or a “humanized” AAV capsid.
  • a peptide (P) can be introduced in said capsids, for example into a variable region of the cap gene, possibly to modify the AAV tropism.
  • the vectors useful in the compositions and methods described herein contain, at a minimum, sequences encoding a selected AAV serotype capsid, e.g., an AAV9 capsid, or a fragment thereof.
  • useful vectors contain, at a minimum, sequences encoding a selected AAV serotype rep protein, e.g., AAV9 rep protein, or a fragment thereof.
  • such vectors may contain both AAV cap and rep proteins.
  • the AAV rep and AAV cap sequences can both be of one serotype origin, e.g., all AAV9 origin.
  • vectors may be used in which the rep sequences are from an AAV serotype, which differs from that which is providing the cap sequences.
  • the rep and cap sequences are expressed from separate sources (e.g., separate vectors, or a host cell and a vector).
  • these rep sequences are fused in frame to cap sequences of a different AAV serotype to form a chimeric AAV vector.
  • the AAV vector comprises a genome and a capsid derived from AAVs of different serotypes.
  • AAVs include AAV2/8 (US 7,282,199), AAV2/5 (available from the National Institutes of Health), AAV2/9 (W02005/033321), AAV2/6 (US 6,156,303), AAVrhlO (W02003/042397), AAVrh74 (W02003/123503), AAV9-rh74 hybrid or AAV9-rh74-Pl hybrid (WO2019/193119; W02020/200499; EP20306005.8).
  • the AAV is of serotype 2, 5, 8 or 9, or an AAVrh74.
  • the claimed vector comprises a capsid selected from the group consisting of: AAV8 capsid, AAV9 capsid, AAV9-rh74 capsid and AAV9-rh74-Pl capsid.
  • the AAV is an AAV of serotype 9 (AAV9).
  • the AAV genome may be either a single stranded (ss) nucleic acid or a double stranded (ds) / self complementary (sc) nucleic acid molecule.
  • the nucleic acid sequence of interest is inserted between the ITR ( « Inverted Terminal Repeat ») sequences of the AAV vector.
  • ITR sequences originate from AAV2 or AAV9, advantageously AAV9.
  • the present invention relates to a recombinant adeno-associated virus (rAAV) vector comprising a nucleic acid molecule as disclosed above.
  • rAAV adeno-associated virus
  • recombinant viral particles can be obtained, e.g., by tri -transfection of 293 HEK cells, by the herpes simplex virus system and by the baculovirus system, or using specific cell lines.
  • the vector titers are usually expressed as viral genomes per ml (vg/ml).
  • a cell comprising the expression system of the invention, or a vector comprising said expression system, as disclosed above.
  • the cell can be any type of cells, i.e. prokaryotic or eukaryotic.
  • the cell can be used for propagation of the vector or can be further introduced (e.g. grafted) in a host or a subject.
  • the expression system or vector can be introduced in the cell by any means known in the art, e.g. by transformation, electroporation or transfection. Vesicles derived from cells can also be used.
  • compositions comprising an expression system, a vector or a cell, as disclosed above, for use as a medicament.
  • the present invention relates to a composition, advantageously a pharmaceutical composition or a drug, comprising an AAVr vector as disclosed above.
  • composition of the invention may comprise other active molecules (other gene therapy products, chemical entities, peptides, proteins, ...), dedicated to the treatment of the same disease or another disease.
  • compositions comprising an expression system, a vector or a cell of the invention.
  • Such compositions comprise a therapeutically effective amount of the therapeutic, and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. or European Pharmacopeia or other generally recognized pharmacopeia for use in animals, and humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • Water is a preferred carrier when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.
  • compositions can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, sustained-release formulations and the like. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the subject.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to release pain at the site of the injection.
  • the composition according to the invention is suitable for administration in humans.
  • the composition is preferably in a liquid form, advantageously a saline composition, more advantageously a phosphate buffered saline (PBS) composition or a Ringer-Lactate solution.
  • PBS phosphate buffered saline
  • the amount of the therapeutic (i.e. an expression system or a vector or a cell) of the invention which will be effective in the treatment of the target diseases can be determined by standard clinical techniques.
  • in vivo and/or in vitro assays may optionally be employed to help predict optimal dosage ranges.
  • the precise dose to be employed in the formulation will also depend on the route of administration, the physical characteristics of the individual under consideration such as sex, age and weight, concurrent medication, other factors and the seriousness of the disease, and should be decided according to the judgment of the practitioner and each patient’s circumstances.
  • Suitable administration should allow the delivery of a therapeutically effective amount of the gene therapy product to the target tissues, especially skeletal muscles and possibly heart and diaphragm.
  • the therapeutic dose is defined as the quantity of viral particles (vg for viral genomes) containing the transgene administered per kilogram (kg) of the subject.
  • typical doses of the vector are of at least IxlO 8 vector genomes per kilogram body weight (vg/kg), such as at least IxlO 9 vg/kg, at least IxlO 10 vg/kg, at least IxlO 11 vg/kg, at least IxlO 12 vg/kg at least IxlO 13 vg/kg, at least IxlO 14 vg/kg, at least 10 15 vg/kg.
  • the dose can be between 5.10 11 vg/kg and 10 14 vg/kg, e.g. 1, 2, 3, 4, 5, 6, 7, 8 or 9.10 13 vg/kg.
  • a lower dose of e.g. 1, 2, 3, 4, 5, 6, 7, 8 or 9.10 12 vg/kg can also be contemplated in order to avoid potential toxicity and /or immune reactions.
  • a dose as low as possible giving a satisfying result in term of efficiency is preferred.
  • Available routes of administration are topical (local), enteral (system-wide effect, but delivered through the gastrointestinal (GI) tract), or parenteral (systemic action, but delivered by routes other than the GI tract).
  • the preferred route of administration of the compositions disclosed herein is parenteral which includes intramuscular administration (i.e. into the muscle) and systemic administration (i.e. into the circulating system).
  • injection encompasses intravascular, in particular intravenous (IV), intramuscular (IM), intraocular, intrathecal or intracerebral administration. Injections are usually performed using syringes or catheters.
  • systemic delivery of the composition comprises administering the composition near a local treatment site, i.e. in a vein or artery nearby a weakened muscle.
  • the invention comprises the local delivery of the composition, which produces systemic effects.
  • This route of administration usually called “regional (loco-regional) infusion”, “administration by isolated limb perfusion” or “high-pressure transvenous limb perfusion” has been successfully used as a gene delivery method in muscular dystrophy.
  • the composition is administered to an isolated limb (loco-regional) by infusion or perfusion.
  • the invention comprises the regional delivery of the composition in a leg and/or arm by an intravascular route of administration, i.e. a vein (transvenous) or an artery, under pressure. This is usually achieved by using a tourniquet to temporarily arrest blood circulation while allowing a regional diffusion of the infused product, as e.g. disclosed by Toromanoff et al. (2008).
  • the composition is injected in a limb of the subject.
  • the limb can be the arm or the leg.
  • the composition is administered in the lower part of the body of the subject, e.g. below the knee, or in the upper part of the body of the subject, e.g., below the elbow.
  • a preferred method of administration according to the invention is systemic administration.
  • Systemic injection opens the way to an injection of the whole body, in order to reach the entire muscles of the body of the subject including the heart and the diaphragm and then a real treatment of these systemic and still incurable diseases.
  • systemic delivery comprises delivery of the composition to the subject such that composition is accessible throughout the body of the subject.
  • systemic administration occurs via injection of the composition in a blood vessel, i.e. intravascular (intravenous or intra-arterial) administration.
  • the composition is administered by intravenous injection, through a peripheral vein.
  • the treatment comprises a single administration of the composition.
  • the presence of the gene therapy product and/or the expression of the functional micro-utrophin, as well as the associated therapeutic benefits, are observed for up to 1 month, or 3 months or 6 months or even 1 year, 2 years, 5 years, 10 years, or even more the whole life of the subject.
  • the subject is preferably a human, but can also be a mouse, a rat, a non-human primate, or a dog.
  • Subjects that could benefit from the compositions of the invention include all patients diagnosed with such a disease or at risk of developing such a disease.
  • a subject to be treated can then be selected based on the identification of mutations or deletions in the gene encoding dystrophin by any method known to the one skilled in the art, including for example sequencing of said gene, and/or through the evaluation of the protein level of expression or activity by any method known to the one skilled in the art. Therefore, said subjects include both subjects already exhibiting symptoms of such a disease and subjects at risk of developing said disease.
  • said subjects include subjects already exhibiting symptoms of such a disease.
  • said subjects are ambulatory patients and early non-ambulant patients.
  • compositions are notably intended for gene therapy in a subject, particularly for the treatment of diseases due the deficiency of the above-identified proteins, especially dystrophin.
  • compositions are notably intended for the treatment of a neuromuscular disease, especially a muscular dystrophy involving a defective dystrophin, i.e. a dystrophic disease.
  • Dystrophic disease in the context of the invention means a disease linked to a defect in the dystrophin gene. This defect can be deletions or mutations leading to low level of expression or absence of expression, introduction of a premature stop codon in the open reading frame, or the production of an inactive protein.
  • Preferred dystrophic diseases are Duchenne and Becker muscular dystrophy (DMD/BMD) caused by mutations of the dystrophin gene. Said mutations can result in the absence or a low level of dystrophin expression, or in the production of a partially or fully inactive, possibly truncated, protein.
  • the present invention relates to a pUTR, a rAAV or a composition as disclosed above for use to treat a dystrophic disease, in particular Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).
  • a dystrophic disease in particular Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).
  • DMD Duchenne muscular dystrophy
  • BMD Becker muscular dystrophy
  • the invention concerns the use of a pUTR, a rAAV or a composition as disclosed above for the preparation of a medicament for the treatment of a dystrophic disease.
  • the present invention provides a method for treating a dystrophic disease, especially DMD and BMD, in a subject, comprising administrating, advantageously by systemic administration, to the subject a pUTR, a rAAV or a composition as disclosed above.
  • a first target of the invention is to provide a safe (not toxic) and non-immunogenic treatment.
  • a further aim is to provide an efficient treatment which allows to postpone, slow down or prevent the development of the disease, and possibly to ameliorate the phenotype of the patient which can be easily monitored at the clinical level.
  • AAV vectors and compositions according to the invention can be used: for ameliorating muscular function. Of particular interest are the skeletal muscles, but also the cardiac muscle and the diaphragm; for ameliorating gait; for ameliorating cardiac function; for ameliorating respiratory function; for prolonging survival, more generally to ameliorate the quality and the expectancy of life.
  • the invention is useful for: increasing muscular force, muscular endurance and/or muscle mass in a subject; reducing fibrosis in a subject; reducing contraction-induced injury in a subject;
  • muscular dystrophy in a subject; reducing degenerating fibers or necrotic fibers in a subject suffering from muscular dystrophy; reducing inflammation in a subject suffering from muscular dystrophy; reducing levels of creatine kinase (or any other dystrophic marker) in a subject suffering from muscular dystrophy; - treating myofiber atrophy and hypertrophy in a subject suffering from muscular dystrophy; decreasing dystrophic calcification in a subject suffering from muscular dystrophy; decreasing fatty infiltration in a subject; decreasing central nucleation in a subject.
  • Figure 1 Domain organization of different forms of dystrophin and utrophin:
  • nNOS neuronal nitric oxide synthase
  • FIG. 2 Activity tests in wild-type mice (wt), mutant mice mdx) and mdx mice treated with micro-utrophins (pUTRb and pUTRl-3)
  • FIG. 3 Muscle function assays in wild-type mice (wt), mutant mice mdx) and mdx mice treated with micro-utrophins (pUTRb and pUTRl-3)
  • mice C57BL/10 (wild-type) and bl 10 mdx (lacking the dystrophin gene). All mouse procedures were done according to protocol approved by the Ethic Committee at the CERFE of Evry animal facility and under appropriate biological containment.
  • the expression cassettes including the AAV9 ITR, the H3 promoter, the human pUTR cDNA and the SV40 PolyA were generated.
  • Adeno-associated virus vectors were produced following a triple transfection protocol using 293 cells in suspension and purified by affinity chromatography.
  • the rAAV production was performed using the Genethon facilities. Administration
  • An LE8811 infrared actimeter from Bioseb comprising:
  • Mice are put one by one in the acquisition zones.
  • the analysis is carried out over one hour and a half of acquisition. Thanks to the detection frames, the following parameters are measured:
  • the percentage of inactivity is measured.
  • the percentage of activity is calculated with the following formula: 100 - percentage or inactivity.
  • mice were tested to determine peak paw grip strength, positioned horizontally with their forepaws on a grip bar using a grip strength meter (MK-380 M; Muromachi Kikai Co., Ltd., Japan), and pulled back slowly and steadily until mice released their grip. This was repeated six times, and peak force for the four-limb paws was measured. Grip strength was normalized for mouse body weight measured on the same date as grip strength.
  • Tetanic force repetitions of electrical stimulation leading to a summation and fusion of tremors.
  • the myogram presents a plateau appearance.
  • Twitch force corresponds to a contraction followed by a relaxation of a muscle in response to a single, short-lasting isolated stimulation of the nerve.
  • mice were anaesthetized (e.g. with xylazine) and intact tibialis anterior (TA) muscles were dissected and placed in an experimental organ bath. Muscles were stimulated by an electric field generated between two platinum electrodes placed longitudinally on either side of the muscle (e.g. square wave pulses 25 V, 0.2 ms in duration, 150 Hz). Muscles were adjusted to the optimum length (Lo) for the development of isometric twitch force and a 5 min recovery period was allowed between stimulations. Optimal muscle length (Lo) and stimulation voltage were determined from micromanipulation of muscle length and a series of twitch contractions that produced maximum isometric twitch force.
  • TA tibialis anterior
  • the percentage recovery score was calculated as described on the TREAT-NMD website (TREAT -NMD SOP M.l. l_001 : http:// www.treat-nmd.eu/downloads/file/sops/dmd /MDX/DMD M.1.1 001.pdf).
  • the mdx mouse presents significant defects in total activity, total distance, total upright position, and maximal speed compared to wild-type animal. In all functional assays, significant benefits were noted with the rAAVs-pUTR treatments.
  • the mdx mice present significant defect compared to wild-type (wt) animal in all assays.
  • the pUTR are efficient transgenes to restore force in mdx animals.
  • a recovery score was established to situate all mice/groups in comparison to mdx animals (0%) and the wild-type mice (100%).
  • Figure 4 presents the recovery scores per assays and the general recovery scores obtained so far for all groups of pUTRs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une micro-utrophine comprenant la structure NTDH1R1R2R3H2R22H4CRD et deux autres domaines de tige choisis dans le groupe constitué par : - les domaines de tige R4 à R10 de l'utrophine; les domaines de tige R16 et R17 de la dystrophine; une séquence d'acide nucléique codant pour une telle micro-utrophine, un vecteur de virus adéno-associé recombinant (rAAV) comprenant une telle séquence, et leur utilisation pour traiter une dystrophie musculaire telle que la dystrophie musculaire de Duchenne (DMD) ou la dystrophie musculaire de Becker (DMB).
PCT/EP2024/070500 2023-07-19 2024-07-19 Nouveaux micro-gènes d'utrophine optimisés Pending WO2025017168A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23186549.4 2023-07-19
EP23186549 2023-07-19

Publications (1)

Publication Number Publication Date
WO2025017168A1 true WO2025017168A1 (fr) 2025-01-23

Family

ID=87426681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/070500 Pending WO2025017168A1 (fr) 2023-07-19 2024-07-19 Nouveaux micro-gènes d'utrophine optimisés

Country Status (1)

Country Link
WO (1) WO2025017168A1 (fr)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
WO2003042397A2 (fr) 2001-11-13 2003-05-22 The Trustees Of The University Of Pennsylvania Methode de detection et/ou d'identification de sequences de virus associes aux adenovirus (aav) et d'isolation de nouvelles sequences ainsi identifiees
WO2005033321A2 (fr) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Variantes des virus associes aux adenovirus (aav), sequences, vecteurs les contenant, et leur utilisation
WO2005049850A2 (fr) 2003-11-14 2005-06-02 University Of Washington Compositions et procedes d'administration de sequence d'acides nucleiques systemiques
US7282199B2 (en) 2001-12-17 2007-10-16 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
WO2008088895A2 (fr) * 2007-01-18 2008-07-24 University Of Missouri-Columbia Mini/microgènes synthétiques de la dystrophine pour redonner de la no-synthase neuronale au sarcolemme
US20090054327A1 (en) * 2006-12-01 2009-02-26 Ervasti James M TAT-utrophin as a protein therapy for dystrophinopathies
WO2013009943A2 (fr) * 2011-07-12 2013-01-17 Regents Of The University Of Minnesota Polypeptides de la micro-utrophine et procédés s'y rapportant
US20140234255A1 (en) * 2012-11-26 2014-08-21 The Curators Of The University Of Missouri Microdystrophin peptides and methods for treating muscular dystrophy using the same
WO2015197869A1 (fr) 2014-06-27 2015-12-30 Genethon Traitement systémique efficace de pathologies dystrophiques
US20190184033A1 (en) * 2016-06-21 2019-06-20 The Curators Of The University Of Missouri Modified dystrophin proteins
WO2019193119A1 (fr) 2018-04-05 2019-10-10 Genethon Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
WO2003042397A2 (fr) 2001-11-13 2003-05-22 The Trustees Of The University Of Pennsylvania Methode de detection et/ou d'identification de sequences de virus associes aux adenovirus (aav) et d'isolation de nouvelles sequences ainsi identifiees
US7282199B2 (en) 2001-12-17 2007-10-16 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
WO2005033321A2 (fr) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Variantes des virus associes aux adenovirus (aav), sequences, vecteurs les contenant, et leur utilisation
WO2005049850A2 (fr) 2003-11-14 2005-06-02 University Of Washington Compositions et procedes d'administration de sequence d'acides nucleiques systemiques
US20090054327A1 (en) * 2006-12-01 2009-02-26 Ervasti James M TAT-utrophin as a protein therapy for dystrophinopathies
WO2008088895A2 (fr) * 2007-01-18 2008-07-24 University Of Missouri-Columbia Mini/microgènes synthétiques de la dystrophine pour redonner de la no-synthase neuronale au sarcolemme
WO2013009943A2 (fr) * 2011-07-12 2013-01-17 Regents Of The University Of Minnesota Polypeptides de la micro-utrophine et procédés s'y rapportant
US20140234255A1 (en) * 2012-11-26 2014-08-21 The Curators Of The University Of Missouri Microdystrophin peptides and methods for treating muscular dystrophy using the same
WO2015197869A1 (fr) 2014-06-27 2015-12-30 Genethon Traitement systémique efficace de pathologies dystrophiques
US20190184033A1 (en) * 2016-06-21 2019-06-20 The Curators Of The University Of Missouri Modified dystrophin proteins
WO2019193119A1 (fr) 2018-04-05 2019-10-10 Genethon Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit
WO2020200499A1 (fr) 2018-04-05 2020-10-08 Genethon Sérotype du virus adéno-associé recombiné hybride modifié par peptide entre aav9 et aavrh74 possédant un tropisme hépatique réduit et une transduction musculaire accrue

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
COLEY ET AL., , HUMAN MOLECULAR GENETICS, vol. 25, no. 1, 2016, pages 130 - 45
DECROUY ET AL., , GEN THER, vol. 4, no. 5, 1997, pages 401 - 8
FOSTER H. ET AL., MOL THER, vol. 16, no. 11, 2008, pages 1825 - 32
KODIPPILI ET AL., HUMAN GENE THERAPY, vol. 29, no. 3, 2018, pages 299 - 311
KOO ET AL., J GENE MED, vol. 13, no. 9, 2011, pages 497 - 506
LAI ET AL., J. CLIN. INVEST., vol. 119, 2009, pages 624 - 635
LARCHER ET AL., PLOS ONE, vol. 9, no. 10, 2014, pages 10371
LE GUINER ET AL., , MOL THER., vol. 22, no. 11, 2014, pages 1923 - 35
MOSER, H., HUM GENET, vol. 66, no. 1, 1984, pages 17 - 40
MUNTONI F ET AL., , LANCET NEUROL, vol. 2, no. 12, 2003, pages 731 - 40
ODOM ET AL., MOL THER., vol. 16, no. 9, 2008, pages 1539 - 45
ODOM GUY L ET AL: "Microutrophin Delivery Through rAAV6 Increases Lifespan and Improves Muscle Function in Dystrophic Dystrophin/Utrophin-deficient Mice", MOLECULAR THERAPY, vol. 16, no. 9, 1 September 2008 (2008-09-01), US, pages 1539 - 1545, XP093111781, ISSN: 1525-0016, DOI: 10.1038/mt.2008.149 *
RODINO-KLAPAC, L.R. ET AL., CURR NEUROL NEUROSCI REP, vol. 13, no. 3, 2013, pages 332
SONG YAFENG ET AL: "Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 25, no. 10, 1 October 2019 (2019-10-01), pages 1505 - 1511, XP036901643, ISSN: 1078-8956, [retrieved on 20191007], DOI: 10.1038/S41591-019-0594-0 *
YAMASHITA K ET AL: "The 8th and 9th tandem spectrin-like repeats of utrophin cooperatively form a functional unit to interact with polarity-regulating kinase PAR-1b", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 391, no. 1, 1 January 2010 (2010-01-01), pages 812 - 817, XP026852773, ISSN: 0006-291X, [retrieved on 20091127], DOI: 10.1016/J.BBRC.2009.11.144 *
YUE ET AL., MOL THER, vol. 14, no. 1, 2006, pages 79 - 87

Similar Documents

Publication Publication Date Title
US20250367328A1 (en) Methods of manufacturing microdystrophin gene therapy constructs
EP3292138B1 (fr) Production de microdystrophinse de grande dimension dans une configuration de vecteur à base d'aav
US20200405810A1 (en) Efficient systemic treatment of dystrophic muscle pathologies
US10301367B2 (en) Compositions and methods for treatment of muscular dystrophy
US10286085B2 (en) Compositions and methods for treatment of muscular dystrophy
EP2933335A1 (fr) Procédé de traitement de neuropathies périphériques et sclérose latérale amyotrophique
US20230321277A1 (en) Novel polynucleotides encoding a human fkrp protein
US20220370640A1 (en) Gene therapy expression system alleviating cardiac toxicity of fkrp
JP7635139B2 (ja) オーバーラップａａｖベクターを使用する大きいサイズのクアシジストロフィンの産生
US20230256117A1 (en) Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
WO2025017168A1 (fr) Nouveaux micro-gènes d'utrophine optimisés
CN116194587A (zh) 一种新的肌肉特异性启动子
US20240409955A1 (en) Auf1 combination therapies for treatment of muscle degenerative disease
WO2025017169A1 (fr) Nouvelles mididystrophines
AU2023312053A1 (en) Auf1 gene therapy for limb girdle muscular dystrophy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24746308

Country of ref document: EP

Kind code of ref document: A1